Efficacy and Safety of Empagliflozin in GSD-Ib Patients

Glycogen Storage Disease Type IB Clinical Trial

Official title:

Efficacy and Safety of Empagliflozin in Patients With Glycogen Storage Disease Type Ib

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05960617
• Other study ID #: XHEC-C-2023-051-2
• Status: Recruiting
• Phase: Phase 2
• Start date: July 15, 2023
• Est. completion date: December 31, 2024

Study information

• Verified date: June 2023
• Source: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
• Contact: Wenjuan Qiu, MD PhD
• Phone: +86-21-25076466
• Email: qiuwenjuan[@]xinhuamed.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Empagliflozin Treatment of GSD-1b patients

Description:

Glycogen storage disease type Ib (GSD-Ib) is a type of genetic disease with a prevalence of approximately 1 in 500,000. In addition to phenotypes common to GSD-I such as hypoglycemia, hypoglycemia, lactatemia, hyperlipidemia, hyperuricemia, and hepatomegaly, GSD-Ib patients also experience neutropenia and dysfunction, causing infections and inflammatory bowel disease (IBD). At present, the only available treatment for neutropenia in GSD-Ib patients is subcutaneous injection of granulocyte-colony stimulating factor (G-CSF). G-CSF increases the number of neutrophils, but does not improve neutrophil dysfunction, and is also associated with the risk of concurrent splenomegaly and malignancy. The most recent research findings demonstrated that substantial accumulation of 1,5-anhydroglucitol-phosphate is the cause of neutropenia and neutrophil dysfunction in GSD Ib patients. Empagliflozin, an SGLT2 inhibitor, is an efficient and secure approach of treating neutropenia in these patients by inhibiting renal glucose and 1,5-anhydroglucitol reabsorption. Our study's objective is to assess the efficacy and safety of empagliflozin (Jardiance®) in patients with GSD Ib.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 31, 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 50 Years

Eligibility

Inclusion Criteria:

1. Patients with glycogen storage disease type Ib (genetically diagnosed) aged = 1 year and = 50 years;

2. Patients meet the diagnostic criteria for Crohn's disease (CD) based on Expert consensus on the diagnosis and treatment of inflammatory bowel disease in Chinese children (2019) or Consensus opinion on the diagnosis and treatment of inflammatory bowel disease in China (2018), or patients meet the diagnostic criteria for recurrent respiratory tract infection based on Clinical diagnosis and treatment for recurrent respiratory tract infection in Chinese children (2022);

3. Subjects and their guardians/clients (< 18 years old) or subjects (= 18 years old) signed the informed consent form.

Exclusion Criteria:

1. Patients with chronic kidney disease (eGFR < 60 ml/min/1.73 m^2) or cirrhosis (Metavir F4);

2. Experiencing symptomatic or severe hypoglycemia within 1 month before the start of this trial;

3. Absolute neutrophil count continued = 1.5 × 10^9/L (= 3 tests, each interval = 5 days);

4. Current active urinary tract infection (until urine routine twice negative);

5. Participating other clinical investigators in the past 1 month;

6. Pregnancy, breast-feeding and having a pregnancy plan;

7. Presence of contraindications to empagliflozin therapy (hypersensitivity to empagliflozin, current or history of gangrene, history of recurrent urinary or genital infections);

8. Patients who are not suitable for participating in the clinical investigator or with low compliance in the investigator 's opinion.

Related Conditions & MeSH terms

• Disease
• Glycogen Storage Disease
• Glycogen Storage Disease Type I
• Glycogen Storage Disease Type IB

Intervention

Drug:
• Empagliflozin
Oral administration of Empagliflozin: The starting dose was 0.3 mg/kg/day in 2 divided doses for 3 months. If the subject had an absolute neutrophil count > 1.0 × 10^9/L and clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained. If the subject had an absolute neutrophil count < 1.0 × 10^9/L but clinical improvement (decreased number of infections and/or decreased IBD activity within 3 months), the maintenance dose was maintained and reassessed 1 month later. If the subject had an absolute neutrophil count < 1.0 × 10^9/L and no clinical improvement (no change in number of infections and/or no change in IBD activity within 3 months), the dose was increased by 0.1 mg/kg/day and reassessed 3 months later. Assessments were then performed every 3 months with the same dose modification criteria as above.

Locations

Country	Name	City	State
China	Xinhua Hospital, Shanghai Jiao Tong University School of Medicine	Shanghai	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from Baseline in Absolute neutrophil count at 1 year	Efficacy of Empaglifozin measured by the change in absolute neutrophil count after 12 months of treatment compared to the period before study	1 year
Primary	Occurrence of hypoglycemia	Safety and tolerability of Empaglifozin measured by hypoglycemia	1 year
Secondary	Number of infections	Efficacy of Empaglifozin measured by the number of respiratory tract, skin, and urinary tract infections	1 year
Secondary	Inflammatory bowel disease activity	Measured as classical Crohn 's disease activity index (CDAI) for adults (range from 0 to 600; remission <150; mildly active disease 150-219; moderately active disease 220- 450; severely active disease = 450) or pediatric Crohn' s disease activity index (PCDAI) for children (range from 0 to 100; remission <10; mildly active disease 10-27.5; moderately active disease 30-37.5; severely active disease 40-100) after 3, 6, 9, and 12 months of treatment compared to the period before study	1 year
Secondary	Endoscopic scores of inflammatory bowel disease	Measured as difference in Crohn 's Disease Simplified Endoscopic Score (SES-CD) (range from 0 to 17; remission 0-2; mild endoscopic activity 3-6; moderate endoscopic activity 7-15; severe endoscopic activity >15) before and after 1 year of empagliflozin treatment	1 year
Secondary	Change of triglycerides	Measured as change of triglycerides (mmol/L) compared to the period before study	1 year
Secondary	Change of total cholesterol	Measured as change of total cholesterol (mmol/L) compared to the period before study	1 year
Secondary	Change of lactate	Measured as change of lactate (mmol/L) compared to the period before study	1 year
Secondary	Change of uric acid	Measured as change of uric acid (mmol/L) compared to the period before study	1 year